Modulation of interferon signaling by hepatitis C virus non-structural 5A protein: implication of genotypic difference in interferon treatment.

FEBS Lett

National Research Laboratory of Hepatitis C Virus, Ilsong Institute of Life Science, Hallym University, Dongan-gu, Anyang, Republic of Korea.

Published: September 2010

AI Article Synopsis

  • The study examines how the NS5A protein of hepatitis C virus (HCV) affects resistance to interferon (IFN) treatment and compares differences between genotypes 1b and 2a.
  • Both genotypes were found to inhibit IFN-α and other antiviral responses similarly, suggesting no significant differences in their IFN responses.
  • The findings imply that other host factors might contribute to the varied IFN treatment outcomes seen in HCV patients, rather than the genotypes alone.

Article Abstract

Interferon (IFN) response rate in hepatitis C virus (HCV) patients has been varied with genotypes. In this study, we investigated the effects of HCV NS5A protein on IFN resistance and compared the genotypic differences of NS5A. We showed that IFN-α-, poly I:C-, and Sendai virus-induced ISRE transcriptional activities were inhibited by both genotype 1b and 2a NS5A protein. We demonstrated that not only genotype 1b but also genotype 2a NS5A exerted the similar extent of IFN-α-induced antiviral activity. We showed that NS5A derived from both genotype 1b and 2a showed no significant differential IFN responses as seen in HCV patients. These data imply that some other host factor may be involved in genotypic differences of IFN antagonism in HCV patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.febslet.2010.08.032DOI Listing

Publication Analysis

Top Keywords

hcv patients
12
hepatitis virus
8
ns5a protein
8
genotypic differences
8
genotype ns5a
8
ns5a
5
modulation interferon
4
interferon signaling
4
signaling hepatitis
4
virus non-structural
4

Similar Publications

Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment.

Clin Mol Hepatol

December 2024

Karsh Division of Gastroenterology and Hepatology, Comprehensive Transplant Center, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality. HCC due to chronic hepatitis B virus (HBV) or C virus (HCV) infection has decreased due to universal vaccination for HBV and effective antiviral therapy for both HBV and HCV, but HCC related to metabolic dysfunction associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD) is increasing. Biannual liver ultrasonography and serum α-fetoprotein are the primary surveillance tools for early HCC detection among high-risk patients (e.

View Article and Find Full Text PDF

Depression is common among people living with HCV and HIV, which contributes to health services utilization (HSU). It is unknown whether successful HCV treatment affects this. We examined depressive symptoms and HSU in people co-infected with HIV-HCV and their association with sustained virologic response (SVR) during the direct-acting antiviral era.

View Article and Find Full Text PDF

"I still can feel the sickness": Withdrawal experiences of people on methadone maintenance treatment.

J Subst Use Addict Treat

December 2024

Department of Social and Behavioral Sciences, School of Global Public Health, New York University, New York, NY 10003, USA; Center for Drug Use and HIV/HCV Research, School of Global Public Health, New York University, New York, NY 10003, USA.

Introduction: Opioid withdrawal is a regular occurrence for many people who use illicit opioids (PWUIO) involving acute physical and psychological pain. Yet, there is very little data on the withdrawal experience of people in methadone maintenance treatment (MMT) and almost none from the patients' experience. Learning more about patients' withdrawal experiences can help to inform policies and practices that are better suited to address withdrawal and may improve patient satisfaction as well as uptake and retention.

View Article and Find Full Text PDF

We report a case of an 87-year-old female with a ruptured hepatocellular carcinoma (HCC). She presented with sudden epigastric and right upper abdominal pain. The physical examination revealed mild tenderness in the right upper abdomen, a positive Murphy's sign, and no jaundice.

View Article and Find Full Text PDF

Background And Objectives: Chronic viral hepatitis is a major public health challenge. The World Health Organization (WHO) and many national programs have set goals for elimination of viral hepatitis by 2030. Screening, Linkage to care (LTC), and access to treatment are very important steps to eliminate viral hepatitis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!